Lung cancer is the deadliest cancer worldwide, accounting for 1.82 million deaths in 2022. The second most deadly form of cancer is colorectum cancer, followed by liver cancer. However, lung cancer is only the sixth leading cause of death worldwide, with heart disease and stroke accounting for the highest share of deaths. Male vs. female cases Given that lung cancer causes the highest number of cancer deaths worldwide, it may be unsurprising to learn that lung cancer is the most common form of new cancer cases among males. However, among females, breast cancer is by far the most common form of new cancer cases. In fact, breast cancer is the most prevalent cancer worldwide, followed by prostate cancer. Prostate cancer is a very close second to lung cancer among the cancers with the highest rates of new cases among men. Male vs. female deaths Lung cancer is by far the deadliest form of cancer among males but is the second deadliest form of cancer among females. Breast cancer, the most prevalent form of cancer among females worldwide, is also the deadliest form of cancer among females. Although prostate cancer is the second most prevalent cancer among men, it is the fifth deadliest cancer. Lung, liver, stomach, colorectum, and oesophagus cancers all have higher deaths rates among males.

In 2022, there were over 9.7 million cancer deaths worldwide. It is projected that the number of deaths due to cancer worldwide will increase to almost 18.5 million by 2050. The most prevalent type of cancer in 2022 was breast cancer with around 48 prevalent cases per 100,000 population. However, lung cancer is by far the deadliest type of cancer.

Lung Cancer Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. In 2022, around 1.82 million cancer deaths, or 19 percent of all cancer deaths worldwide were attributed to lung cancer. Long-term smoking is known to be a major cause of lung cancer. People who never quit smoking are 24 percent more likely to die before age 65 than people who never smoked in their lives.

Treatment In 2023, it was estimated that there were around 4,492 cancer immunotherapy products in R&D phases, as well as another 3,622 other cancer products in the R&D product pipeline. In the same year, it was projected that there were 965 active drugs for breast cancer, as well as 925 active drugs for non-small cell lung cancer.

Lung cancer had the highest rate of death among all cancer types worldwide in 2022. In that year, there were around 17 deaths from trachea, bronchus and lung cancer per 100,000 population. The death rate for all cancers was 91.1 per 100,000 population. This statistic shows the rate of cancer deaths worldwide in 2022, by type of cancer.

Breast cancer was the cancer type with the highest rate of death among females worldwide in 2022. That year, there were around 13 deaths from breast cancer among females per 100,000 population. The death rate for all cancers among females was 76.4 per 100,000 population. This statistic displays the rate of cancer deaths among females worldwide in 2022, by type of cancer.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

https://max-website20-images.s3.ap-south-1.amazonaws.com/MHC_Digital_Treatments_Available_For_Blood_Cancer_Part_13_925x389pix_150322n_01_dc4d07f20e.jpg" alt="Is Blood Cancer Curable - Types, Diagnosis & Cure | Max Hospital">

The "Cancer and Deaths Dataset: 1990~2019 Globally" is a comprehensive dataset containing information on cancer incidence and mortality rates across the world from 1990 to 2019.

The dataset is an excellent resource for researchers, healthcare professionals, and policymakers who are interested in understanding the global burden of cancer and its impact on populations.

[ Total 9 file , 160 columns, All the countries, 30Years data ]

>In 2017, 9.6 million people are estimated to have died from the various forms of cancer. Every sixth death in the world is due to cancer, making it the second leading cause of death – second only to cardiovascular diseases.1

Progress against many other causes of deaths and demographic drivers of increasing population size, life expectancy and — particularly in higher-income countries — aging populations mean that the total number of cancer deaths continues to increase. This is a very personal topic to many: nearly everyone knows or has lost someone dear to them from this collection of diseases.

## Data vastness of this dataset: 01. annual-number-of-deaths-by-cause data. 02. total-cancer-deaths-by-type data. 03. cancer-death-rates-by-age data. 04. share-of-population-with-cancer-types data. 05. share-of-population-with-cancer data. 06. number-of-people-with-cancer-by-age data. 07. share-of-population-with-cancer-by-age data. 08. disease-burden-rates-by-cancer-types data. 09. cancer-deaths-rate-and-age-standardized-rate-index data.

For both sexes of all ages, the total number of cancer deaths was estimated to be approximately 9.74 million in 2022. Almost one fifth of these deaths were from lung cancer. This statistic describes the distribution of cancer deaths worldwide in 2022, sorted by type of cancer.

Additional file 2. Table S1 Total cancer deaths, years of life lost (YLLs), and potential gains in life expectancy (PGLEs) by eliminating total cancer-related deaths, by world region, sex, and HDI, 2022. Table S2 Total cancer deaths and premature cancer deaths, by country and sex, 2022. Table S3 Years of life lost (YLLs) and potential gains in life expectancy (PGLEs) caused by total cancer deaths and premature cancer deaths, by country and sex, 2022. Table S4 Years of life lost (YLLs) and potential gains in life expectancy (PGLEs) caused by total cancer deaths and premature cancer deaths worldwide, by cancer site and sex, 2022. Table S5 The proportions (%) of years of life lost (YLLs) attributable to cancer-related premature deaths in 2022, by cancer site, region, and sex [% (95% UI)]. Table S6 The leading cause of years of life lost (YLLs) due to premature cancer deaths, by country and sex, 2022. Table S7 The potential gains in life expectancy (PGLEs) by eliminating premature cancer deaths in 2022, by cancer site, region, and sex (years, 95% UI). Table S8 The leading cause of potential gains in life expectancy (PGLEs) attributable to premature cancer deaths, by country and sex, 2022.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

BackgroundThe exponential growth of the cancer burden attributable to metabolic factors deserves global attention. We investigated the trends of cancer mortality attributable to metabolic factors in 204 countries and regions between 1990 and 2019.MethodsWe extracted data from the Global Burden of Disease Study (GBD) 2019 and assessed the mortality, age-standardized death rate (ASDR), and population attributable fractions (PAFs) of cancers attributable to metabolic factors. Average annual percentage changes (AAPCs) were calculated to assess the changes in the ASDR. The cancer mortality burden was evaluated according to geographic location, SDI quintiles, age, sex, and changes over time.ResultsCancer attributable to metabolic factors contributed 865,440 (95% UI, 447,970-140,590) deaths in 2019, a 167.45% increase over 1990. In the past 30 years, the increase in the number of deaths and ASDR in lower SDI regions have been significantly higher than in higher SDI regions (from high to low SDIs: the changes in death numbers were 108.72%, 135.7%, 288.26%, 375.34%, and 288.26%, and the AAPCs were 0.42%, 0.58%, 1.51%, 2.36%, and 1.96%). Equatorial Guinea (AAPC= 5.71%), Cabo Verde (AAPC=4.54%), and Lesotho (AAPC=4.42%) had the largest increase in ASDR. Large differences were observed in the ASDRs by sex across different SDIs, and the male-to-female ratios of ASDR were 1.42, 1.50, 1.32, 0.93, and 0.86 in 2019. The core population of death in higher SDI regions is the age group of 70 years and above, and the lower SDI regions are concentrated in the age group of 50-69 years. The proportion of premature deaths in lower SDI regions is significantly higher than that in higher SDI regions (from high to low SDIs: 2%, 4%, 7%, 7%, and 9%). Gastrointestinal cancers were the core burden, accounting for 50.11% of cancer deaths attributable to metabolic factors, among which the top three cancers were tracheal, bronchus, and lung cancer, followed by colon and rectum cancer and breast cancer.ConclusionsThe cancer mortality burden attributable to metabolic factors is shifting from higher SDI regions to lower SDI regions. Sex differences show regional heterogeneity, with men having a significantly higher burden than women in higher SDI regions but the opposite is observed in lower SDI regions. Lower SDI regions have a heavier premature death burden. Gastrointestinal cancers are the core of the burden of cancer attributable to metabolic factors.

** Description**

This dataset contains data about lung cancer Mortality and is a comprehensive collection of patient information, specifically focused on individuals diagnosed with cancer. This dataset contains comprehensive information on 800,000 individuals related to lung cancer diagnosis, treatment, and outcomes. With 16 well-structured columns. This large-scale dataset is designed to aid researchers, data scientists, and healthcare professionals in studying patterns, building predictive models, and enhancing early detection and treatment strategies.

🌍 The Societal Impact of Lung Cancer

Lung cancer is not just a disease — it's a global crisis that steals time, health, and hope from millions of people every year. As the #1 cause of cancer deaths worldwide, it takes more lives annually than breast, colon, and prostate cancer combined.

But behind every statistic is a story:

A parent who never saw their child graduate.

A worker who had to leave their job too soon.

A community that lost a leader, a friend, a neighbor.

Why does this matter? Lung cancer often goes undetected until it's too late. It’s aggressive, silent, and devastating — especially in underserved areas where early detection is rare and treatment options are limited. It doesn’t just affect patients. It affects families, economies, and healthcare systems on a massive scale.

This dataset represents more than numbers. It represents 800,000 real-world stories — people who can help us unlock patterns, train models, and advance life-saving research.

By working with this data, you're not just analyzing a dataset — you're stepping into the fight against one of humanity’s deadliest diseases.

Let’s turn insight into impact. (😊The above descriptions is generated with the help of AI, Just wanted to share this dataset That all. Thank you)

Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 17.600 % in 2021. This records an increase from the previous number of 16.900 % for 2020. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 17.050 % from Dec 2000 (Median) to 2021, with 22 observations. The data reached an all-time high of 18.300 % in 2001 and a record low of 16.200 % in 2012. Cuba CU: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Cuba – Table CU.World Bank.WDI: Social: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).;World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).;Weighted average;This is the Sustainable Development Goal indicator 3.4.1 [https://unstats.un.org/sdgs/metadata/].

Lung cancer was the cancer type with the highest rate of death among males worldwide in 2022. In that year there were around 25 deaths from trachea, bronchus and lung cancer among males per 100,000 population. The death rate for all cancers among males was 109 per 100,000 population. This statistic shows the rate of cancer deaths among males worldwide in 2022, by type of cancer.

These cancer data were collected from Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries and the World Cancer Research Fund, which contain gender and country-classified data on mortality and incidence.

Some data sheets with ASR - Age-standardized rate (ASR) *Age-standardized rate (ASR) is a summary of the cancer rate in a population, adjusted for age. It's used to compare cancer rates across populations with different age structures.

According to Cognitive Market Research, the global Cancer Diagnosis market size was USD 109614.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 6.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 32884.35 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The consumables category is the fastest growing segment of the Cancer Diagnosis industry

Market Dynamics of Cancer Diagnosis Market

Key Drivers for Cancer Diagnosis Market

Increasing Rate of Cancer Diagnostics to Boost Market Growth

The rising global incidence of cancer, which affects millions of people a year, is a primary driver of the need for diagnostic testing. Numerous factors contribute to this tendency, such as the aging population, which increases the risk of developing some cancers in older adults. Changes in lifestyle, including poor eating habits, inactivity, and increased use of alcohol and tobacco, have also contributed to an increase in cancer incidence. Environmental factors, such as exposure to chemicals and hazardous compounds, exacerbate the problem and increase the risk of developing cancer. Therefore, as early detection and diagnosis are becoming more and more important to patients and healthcare professionals, effective cancer diagnostics are essential. The market for cancer diagnostics is expanding as a result of the increased emphasis on prompt and precise cancer detection, which highlights the value of novel diagnostic procedures. For Instance, in 2023, the Pan American Health Organization (PAHO) projects that there will be 20 million new cases and 10 million deaths, and by 2040, nearly 30 million cases will be reported annually.

Innovations in Diagnostic Technologies to Drive Market Growth

The market for cancer diagnostics is expanding as a result of advancements in diagnostic technologies that have greatly improved the precision and effectiveness of cancer detection. For example, non-invasive cancer biomarker identification in physiological fluids is made possible by liquid biopsies, which offer vital insights into tumor dynamics and therapy response. In a similar vein, molecular diagnostics has transformed the detection of particular genetic abnormalities and changes linked to different types of cancer, allowing for more individualized treatment strategies. High-resolution images of tumors are provided by advanced imaging methods like MRI and PET scans, which help with accurate staging and localization. Better patient outcomes result from these technical developments because they increase overall diagnosis accuracy and enable early intervention. The ongoing development of these cutting-edge diagnostic instruments is propelling market expansion and revolutionizing cancer treatment.

Restraint Factor for the Cancer Diagnosis Market

The High Price of Cutting-Edge Diagnostic Technology Will Limit Market Growth

The market for cancer diagnostics is severely hampered by the high price of sophisticated diagnostic tools. Advanced diagnostic instruments, such as molecular tests and imaging technologies, are frequently expensive, which limits healthcare facilities' access to them, especially in settings with limited resources. These institutions' capacity to provide thorough cancer screening and diagnostic services is restricted by this financial barrier, which eventually affects patient outcomes. These financial difficulties are further exacerbated by the costs associated with the development, research, and regulatory approval of new diagnostic instruments. Companies have to spend a lot of money to comply with...

Users can access data about cancer statistics, specifically incidence and mortality worldwide for the 27 major types of cancer. Background Cancer Mondial is maintained by the Section of Cancer Information (CIN) of International Agency for Research on Cancer by the World Health Organization. Users can access CIN databases including GLOBOCAN, CI5(Cancer Incidence in Five Continents), WHO, ACCIS(Automated Childhood Cancer Information System), ECO (European Cancer Observatory), NORDCAN and Survcan. User functionality Users can access a variety of databases. CIN Databases: GLOBOCAN provides acces s to the most recent estimates (for 2008) of the incidence of 27 major cancers and mortality from 27 major cancers worldwide. CI5 (Cancer Incidence in Five Continents) provides access to detailed information on the incidence of cancer recorded by cancer registries (regional or national) worldwide. WHO presents long time series of selected cancer mortality recorded in selected countries of the world. Collaborative projects: ACCIS (Automated Childhood Cancer Information System) provides access to data on cancer incidence and survival of children collected by European cancer registries. ECO (European Cancer Observatory) provides access to the estimates (for 2008) of the incidence of, and mortality f rom 25 major cancers in the countries of the European Union (EU-27). NORDCAN presents up-to-date long time series of cancer incidence, mortality, prevalence and survival from 40 cancers recorded by the Nordic countries. SurvCan presents cancer survival data from cancer registries in low and middle income regions of the world. Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available.

IntroductionThe burden of cancer-related mortality of common malignancies has been reported worldwide. However, whether bone cancer (BC), as a highly aggressive and heterogeneous group of rare cancers, followed a similar or distinct epidemiological pattern during such process remains largely unknown. We aimed to analyze the mortality and the temporal trends of BC in relation to gender, age, and premature death in Shanghai, China.MethodsWe conducted a population-based analysis of the mortality data of BC in Shanghai Pudong New Area (PNA) from 2005 to 2020. The epidemiological characteristics and long-term trends in crude mortality rates (CMRs), age-standardized mortality rates worldwide (ASMRWs), and rate of years of life lost (YLL) was analyzed using the Joinpoint regression program. The demographic and non-demographic factors affecting the mortality rate were evaluated by the decomposition method.ResultsThere are 519 BC-specific deaths accounting for 0.15% of all 336,823 deaths and 0.49% of cancer-specific death in PNA. The CMR and ASMRW of BC were 1.15/105 person-year and 0.61/105 person-year, respectively. The YLL due to premature death from BC was 6,539.39 years, with the age group of 60–69 years having the highest YLL of 1,440.79 years. The long-term trend of CMR, ASMRW, and YLL rate significantly decreased by −5.14%, −7.64%, and −7.27%, respectively, per year (all p < 0.05) in the past 16 years. However, the proportion of BC-specific death within the total cancer-specific death dropped to a plateau without further improvement since 2016, and a remarkable gender and age disparity was noticed in the observed reduction in mortality. Specifically, the elderly benefited less but accounted for a larger percentage of BC population in the last decades. Although the overall mortality of BC decreased, there was still a significant upward trend toward an increased mortality rate caused by the aging of the BC patients.ConclusionOur study provides novel insights on the epidemiological characteristics and longitudinal dynamics of BC in a fast urbanization and transitioning city. As a rare disease affecting all ages, the burden of BC among the elderly emerged to form an understudied and unmet medical need in an aging society.

Cancer is one of the biggest health challenges worldwide. As of 2021, around 15% of all deaths were cancer deaths, making it one of the most common causes of death globally.

Cancers are a group of diseases in which abnormal cells multiply rapidly and can grow into tumors. They can develop in different parts of the body and, in some cases, spread to other organs through the blood and lymph systems.

As the global population grows larger and older, the number of cancer cases has also increased. However, the age-standardized death rate from cancer has declined over time in many countries — due to improvements in diagnosis, research, medical advances, and public health efforts, as well as reductions in risk factors such as smoking and some cancer-causing pathogens.

On this page, we explore global data and research on different types of cancer. This can help us better understand the risk factors for cancer, how cancer risks vary across the lifespan, how they differ worldwide, and how they have changed over time.

In 2010, cancer deaths accounted for more than 15% of all deaths worldwide, and this fraction is estimated to rise in the coming years. Increased cancer mortality has been observed in immigrant populations, but a comprehensive analysis by country of birth has not been conducted. We followed all individuals living in Sweden between 1961 and 2009 (7,109,327 men and 6,958,714 women), and calculated crude cancer mortality rates and age-standardized rates (ASRs) using the world population for standardization. We observed a downward trend in all-site ASRs over the past two decades in men regardless of country of birth but no such trend was found in women. All-site cancer mortality increased with decreasing levels of education regardless of sex and country of birth (p for trend <0.001). We also compared cancer mortality rates among foreign-born (13.9%) and Sweden-born (86.1%) individuals and determined the effect of education level and sex estimated by mortality rate ratios (MRRs) using multivariable Poisson regression. All-site cancer mortality was slightly higher among foreign-born than Sweden-born men (MRR = 1.05, 95% confidence interval 1.04–1.07), but similar mortality risks was found among foreign-born and Sweden-born women. Men born in Angola, Laos, and Cambodia had the highest cancer mortality risk. Women born in all countries except Iceland, Denmark, and Mexico had a similar or smaller risk than women born in Sweden. Cancer-specific mortality analysis showed an increased risk for cervical and lung cancer in both sexes but a decreased risk for colon, breast, and prostate cancer mortality among foreign-born compared with Sweden-born individuals. Further studies are required to fully understand the causes of the observed inequalities in mortality across levels of education and countries of birth.

BACKGROUND Comprehensive analyses of statistical data on breast cancer incidence, mortality, and associated risk factors are of great value for decision-making related to reducing the disease burden of breast cancer. METHODS: Based on data from the Annual Report of China Tumour Registry and the Global Burden of Disease (GBD), we conducted summary and trend analyses of incidence and mortality rates of breast cancer in Chinese women from 2014 to 2018 for urban and rural areas in the whole, eastern, central, and western parts of the country, and projected the incidence and mortality rates of breast cancer for 2019 in comparison with the GBD 2019 estimates. And the comparative risk assessment framework estimated risk factors contributing to breast cancer deaths and disability-adjusted life years (DALYs) from GBD. RESULTS: The Annual Report of the Chinese Tumour Registry showed that showed that the mortality rate of breast cancer declined and the incidence rate remained largely unchanged from 2014 to 2018. There was a significant increasing trend in incidence rates among urban and rural women in eastern China and rural women in central China, whereas there was a significant decreasing trend in mortality rates among rural women in China. The two data sources have some differences in their predictions of breast cancer in China in 2019. The GBD data estimated the age-standard DALYs rates of high body-mass index, high fasting plasma glucose and diet high in red meat, which are the top three risk factors attributable to breast cancer in Chinese women, to be 29.99/100,000, 13.66/100,000 and 13.44/100,000, respectively. Conclusion: The trend of breast cancer incidence and mortality rates shown in the Annual Report of China Tumour Registry indicates that China has achieved remarkable results in reducing the burden of breast cancer, but there is still a need to further improve breast cancer screening and early diagnosis and treatment, and to improve the system of primary prevention. The GBD database provides risk factors for breast cancer in the world, Asia, and China, and lays the foundation for research on effective measures to reduce the burden of breast cancer.